Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices

NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence

(2019) Ash Bullement et al.   PHARMACOECONOMICS

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues

(2018) Patricia M. Danzon   PHARMACOECONOMICS

The implications of external price referencing on pharmaceutical list prices in Europe

(2018) Marcell Csanádi et al.   Health Policy and Technology

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates

(2018) Jaime Espin et al.   Applied Health Economics and Health Policy

Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia

(2017) Steven G. Morgan et al.   HEALTH POLICY

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

(2017) Kim Pauwels et al.   Frontiers in Pharmacology

Actual costs of cancer drugs in 15 European countries

(2016) Wim H van Harten et al.   LANCET ONCOLOGY

Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force

(2016) Praveen Thokala et al.   VALUE IN HEALTH

The End of the International Reference Pricing System?

(2015) Ulf Persson et al.   Applied Health Economics and Health Policy

A Systematic Review of Stakeholder Engagement in Comparative Effectiveness and Patient-Centered Outcomes Research

(2014) Thomas W. Concannon et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Price Dynamics Of External Reference Pricing-Based Systems In Europe

(2014) C. Rémuzat et al.   VALUE IN HEALTH

Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

(2013) Patricia Danzon et al.   HEALTH ECONOMICS

Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries

(2013) Christine Leopold et al.   HEALTH POLICY

How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand

(2013) Deborah Gleeson et al.   HEALTH POLICY

Key principles for the improved conduct of health technology assessments for resource allocation decisions

(2008) Michael F. Drummond et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE